BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 326 filers reported holding BIO-TECHNE CORP in Q4 2018. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $134,187,000 | -18.1% | 472,491 | -0.0% | 0.60% | -15.4% |
| Q2 2022 | $163,866,000 | -22.4% | 472,726 | -3.0% | 0.71% | -9.7% |
| Q1 2022 | $211,120,000 | -15.7% | 487,530 | +0.7% | 0.78% | -7.8% |
| Q4 2021 | $250,377,000 | +5.0% | 483,969 | -1.6% | 0.85% | -0.5% |
| Q3 2021 | $238,364,000 | -7.2% | 491,909 | -13.8% | 0.85% | -3.9% |
| Q2 2021 | $256,954,000 | +7.9% | 570,680 | -8.5% | 0.89% | +5.3% |
| Q1 2021 | $238,227,000 | -14.3% | 623,745 | -28.8% | 0.84% | -15.5% |
| Q4 2020 | $278,093,000 | +27.7% | 875,745 | -0.3% | 1.00% | +11.3% |
| Q3 2020 | $217,704,000 | -13.7% | 878,795 | -8.1% | 0.90% | -16.2% |
| Q2 2020 | $252,408,000 | -2.3% | 955,838 | -29.9% | 1.07% | -20.8% |
| Q1 2020 | $258,400,000 | -12.8% | 1,362,724 | +0.9% | 1.35% | +9.9% |
| Q4 2019 | $296,426,000 | +11.8% | 1,350,399 | -0.3% | 1.23% | +6.7% |
| Q3 2019 | $265,098,000 | -5.9% | 1,354,821 | +0.3% | 1.15% | -9.0% |
| Q2 2019 | $281,740,000 | +5.9% | 1,351,337 | +0.8% | 1.26% | -0.9% |
| Q1 2019 | $266,128,000 | +36.3% | 1,340,357 | -0.6% | 1.28% | +17.8% |
| Q4 2018 | $195,229,000 | -40.3% | 1,349,009 | -15.8% | 1.08% | -28.8% |
| Q3 2018 | $327,086,000 | +16.1% | 1,602,498 | -15.8% | 1.52% | +7.3% |
| Q2 2018 | $281,708,000 | -2.8% | 1,904,079 | -0.8% | 1.42% | -5.5% |
| Q1 2018 | $289,854,000 | +15.3% | 1,919,056 | -1.1% | 1.50% | +13.6% |
| Q4 2017 | $251,409,000 | +6.9% | 1,940,629 | -0.3% | 1.32% | -0.8% |
| Q3 2017 | $235,272,000 | +2.1% | 1,946,171 | -0.8% | 1.33% | -1.4% |
| Q2 2017 | $230,405,000 | +16.4% | 1,960,895 | +0.7% | 1.35% | +11.0% |
| Q1 2017 | $197,872,000 | +56.8% | 1,946,604 | +58.6% | 1.22% | +51.1% |
| Q4 2016 | $126,234,000 | -5.9% | 1,227,596 | +0.3% | 0.80% | -9.4% |
| Q3 2016 | $134,084,000 | -4.4% | 1,224,511 | -1.6% | 0.89% | -5.1% |
| Q2 2016 | $140,281,000 | +18.8% | 1,243,952 | -0.4% | 0.94% | +11.4% |
| Q1 2016 | $118,074,000 | +4.9% | 1,249,198 | -0.1% | 0.84% | +2.1% |
| Q4 2015 | $112,563,000 | +7.8% | 1,250,704 | +10.7% | 0.82% | +5.1% |
| Q3 2015 | $104,432,000 | +221.6% | 1,129,485 | +242.5% | 0.78% | +254.8% |
| Q2 2015 | $32,470,000 | -3.0% | 329,743 | -1.2% | 0.22% | -2.6% |
| Q1 2015 | $33,486,000 | +7.0% | 333,888 | -1.4% | 0.23% | +5.6% |
| Q4 2014 | $31,301,000 | – | 338,754 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |